Refining Therapeutic Approaches in Relapsed/Refractory Multiple Myeloma: Expert Guidance on Bispecific Antibody Therapy Optimization
Expert faculty provide a comprehensive overview of bispecific antibodies in relapsed/refractory multiple myeloma, including clinical considerations, common toxicities, and prophylaxis and management strategies.
Category
Format
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ABIM Medical Knowledge
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
Optimizing Patient Outcomes - Metastatic Castration-Resistant Prostate Cancer: Systemic Therapy Updates
It is important to stay up to date with the latest therapy options available, review the latest mCRPC systemic therapy recommendations, and understand the data behind them.
Category
  • Prostate Cancer
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Event date April 28, 2025
Cost $0.00
NCCN Tumor Boards: T-Cell Engager Therapy for Diffuse Large B-Cell Lymphoma: Bispecific Antibodies for Relapsed/Refractory Disease
T-cell engager therapy with bispecific antibodies is emerging as a promising treatment option for patients with heavily pretreated DLBCL. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Event date April 30, 2025
Cost $0.00
Optimizing Patient Outcomes - Targeted Therapies for Thyroid Carcinoma
Thyroid carcinoma is a rare disease; however, it is the seventh most common cancer diagnosed in those assigned female at birth. Greater attention to rare diseases is needed to improve treatment options in general, and specifically for anaplastic thyroid carcinoma.
Category
  • Thyroid Cancer
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Event date May 21, 2025
Cost $0.00
NCCN Tumor Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer
In recent years, several new systemic therapy regimens were approved by the FDA as additional neoadjuvant or adjuvant treatment options for eligible patients with resectable NSCLC and included in the NCCN Guidelines for NSCLC. Clinicians need to be aware of the updated treatment recommendations to ensure optimal outcomes for patients with early-stage NSCLC.
Category
  • Lung Cancers
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Event date May 22, 2025
Cost $0.00

Pages